Currently, numerous promising immunotherapy drugs, including PD-1/PD-L1, interleukin-2 (IL-2), and interferon (IFN) blocking agents, have been approved for the treatment of ccRCC 3, and the overall therapeutic effect is satisfactory 4. Here, IL2 is linked to nonpapillary renal cell carcinoma.